Bloomsbury Genetic Therapies

bloomsbury genetic therapies ("bloomsbury") is a biotechnology company, developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases based on clinically proven gene therapy technologies. launched in october 2022 with £5m in seed funding from ucl technology fund, the company is a spin-out of university college london and is underpinned by world-leading gene therapy and rare disease expertise from the company’s academic founders, professor paul gissen, professor manju kurian, professor ahad rahim and professor simon waddington. bloomsbury is building a pipeline of highly differentiated first- or best-in-class programs.